DataString Consulting Company Logo
DataString Consulting Company Logo
Icosapent Ethyl Market
Home»Recent Reports»Icosapent Ethyl Market

Icosapent Ethyl Market

Author: Debadatta Patel - Senior Consultant, Report ID - DS1805038, Published - May 2025

Segmented in Dosage Form (Oral Drug, Injectable Formulation, Topical Administration), Therapy Area (Cardiovascular Diseases, Hypertriglyceridemia, Dietary Supplement, Others), Manufacturing Process, End-User and Regions - Global Industry Analysis, Size, Share, Trends, and Forecast 2024 – 2034

Share this report:

Global Icosapent Ethyl Market Outlook

The market, for Icosapent ethyl was estimated at $1.1 billion in 2024; and it is anticipated to increase to $2.8 billion by 2030 with projections indicating a growth to around $5.9 billion by 2035. This expansion represents a compound annual growth rate (CAGR) of 16.3% over the forecast period. The rise in the ICOSAPENT ETHYL market can be attributed to key factors; the impact of cutting edge medical research advancements; heightened awareness surrounding lifestyle linked illnesses; and the growing acceptance of innovative healthcare options as well as ICOSAPENT ETHYLs effectiveness in combating elevated triglyceride levels has solidified its importance in the realm of healthcare. Furthermore the use of cost production techniques and the acquisition of patents by prominent pharmaceutical companies also contribute significantly to the markets success and ensure its continued relevance, in the years ahead.


When looking closely at ICOSAPENT ETHYL itself is a prescription drug well known for its efficacy in lowering triglyceride levels in adults with hypertriglyceridemia. Issues such as its purity and proven effectiveness make it a popular choice among doctors and patients alike. It is commonly used in the field of health but ongoing research hints at potential benefits for cognitive function and inflammatory conditions. Trends like medicine and the growing demand for high purity medications play key roles in shaping the future need, for ICOSAPENT ETHYL.


Market Size Forecast & Key Insights

2019
$1.1B2024
2029
$5.1B2034

Absolute Growth Opportunity = $4.0B

The Icosapent Ethyl market is projected to grow from $1.1 billion in 2024 to $5.1 billion in 2034. This represents a CAGR of 16.3%, reflecting rising demand across Cardiovascular Disease Management, Clinical Research Trials and Dietary Supplement Manufacturing.

The Icosapent Ethyl market is set to add $4.0 billion between 2024 and 2034, with manufacturer targeting Hypertriglyceridemia & Dietary Supplement Therapy Area projected to gain a larger market share.

With Increasing prevalence of cardiovascular diseases, and Advancements in pharmaceutical technology, Icosapent Ethyl market to expand 353% between 2024 and 2034.

Opportunities in the Icosapent Ethyl Market

Strategic Collaborations

In the competitive pharmaceutical sector forming strategic alliances emerges as a promising path, for expansion and development.

Tapping Untapped Segments and Technological Innovations

As a component in the pharmaceutical field ICOSAPENT ETHYL is found in medicines that help reduce triglyceride levels in a persons blood. Yet many developing markets do not only have high quality medications to lower lipids. Businesses could benefit from this opportunity by offering affordable ICOSAPENT ETHYL based drugs in these areas with a specific focus on densely populated regions, in Asia and Africa.

The ongoing progress in the sector has led to the creation of more accurate and effective methods, for administering medications. In the case of ICOSAPENT ETHYL this could mean the introduction of encapsulation techniques to boost its efficacy and drive up interest in the product. The cholesterol lowering feature of ICOSAPENT ETHYL can be maximized by incorporating these drug delivery methods driven by technology.

Growth Opportunities in North America and Europe

Europe Outlook

Europe is becoming a market for ICOSAPENT ETHYL due to its well developed healthcare industry and the growing use of ICOSAPENT ETHYL in pharmaceutical settings. One of the factors boosting the ICOSAPENT ETHYL market in Europe is the increasing awareness of its advantages in treating cardiovascular conditions. Competition among market players, in Europe is fierce as leading companies focus on research and development to introduce groundbreaking solutions.

North America Outlook

The American market for ICOSAPENT ETHYL presents promising opportunities due to its growing use in various applications. The high prevalence of heart diseases and the resulting demand for treatments are key factors driving the ICOSAPENT ETHYL market in this region. Competition is fierce among industry leaders who are employing strategies like acquisitions, collaborations and product launches to stay ahead. The expansion of ICOSAPENT ETHYL in North America is also driven by the healthcare infrastructure and increasing awareness about its benefits, for cardiovascular health. The United States holds a role in influencing market trends and is projected to remain a dominant force in the foreseeable future. Additionally sustained research and development efforts by industry participants to uncover uses for ICOSAPENT ETHYL point towards exciting growth prospects, in this region.

North America Outlook

The American market for ICOSAPENT ETHYL presents promising opportunities due to its growing use in various applications. The high prevalence of heart diseases and the resulting demand for treatments are key factors driving the ICOSAPENT ETHYL market in this region. Competition is fierce among industry leaders who are employing strategies like acquisitions, collaborations and product launches to stay ahead. The expansion of ICOSAPENT ETHYL in North America is also driven by the healthcare infrastructure and increasing awareness about its benefits, for cardiovascular health. The United States holds a role in influencing market trends and is projected to remain a dominant force in the foreseeable future. Additionally sustained research and development efforts by industry participants to uncover uses for ICOSAPENT ETHYL point towards exciting growth prospects, in this region.

Europe Outlook

Europe is becoming a market for ICOSAPENT ETHYL due to its well developed healthcare industry and the growing use of ICOSAPENT ETHYL in pharmaceutical settings. One of the factors boosting the ICOSAPENT ETHYL market in Europe is the increasing awareness of its advantages in treating cardiovascular conditions. Competition among market players, in Europe is fierce as leading companies focus on research and development to introduce groundbreaking solutions.

Growth Opportunities in North America and Europe

Established and Emerging Market's Growth Trend 2025–2034

1

Major Markets : U.S., Germany, Japan, China, UK are expected to grow at 15.6% to 22.8% CAGR

2

Emerging Markets : Brazil, South Africa, Indonesia are expected to grow at 12.2% to 17.0% CAGR

Market Analysis Chart

The market for ICOSAPENT ETHYL is experiencing growth due to various important factors driving its expansion forward globally and notably linked to the increasing prevalence of cardiovascular diseases worldwide and the proven efficacy of ICOSAPENT ETHYL in reducing triglyceride levels—a pivotal risk factor in this context. As healthcare professionals gain an appreciation for the advantages offered by this treatment option it is gradually making its mark in the medical arena promoting favorable progress, within the market. However challenges and limitations are present that pose obstacles.

Recent Developments and Technological Advancement

December 2024

GenovaPharm introduced Venova as a form of ICOSAPENT ETHYL that is highly purified and is said to offer improved effectiveness in preventing cardiovascular events.

November 2024

Manufacturer MedSynthesis has revealed plans for an expansion, at their ICOSAPENT ETHYL production plant to increase the global supply.

August 2024

BioClinix introduced a version of ICOSAPENT ETHYL that includes additional essential micronutrients to enhance absorption and improve treatment effectiveness.

ICOSAPENT ETHYL has seen a rise within its industry lately thanks to its potential therapeutic benefits for cardiovascular conditions. The increased attention, on heart health treatments has contributed to the increased interest and usage of this derivative of Omega 2 fatty acids.

Impact of Industry Transitions on the Icosapent Ethyl Market

As a core segment of the Nutraceuticals industry, the Icosapent Ethyl market develops in line with broader industry shifts. Over recent years, transitions such as Integration into Dietary Supplements and Pioneering in Cardiovascular Treatments have redefined priorities across the Nutraceuticals sector, influencing how the Icosapent Ethyl market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.

1

Integration into Dietary Supplements:

The diverse uses of ICOSAPENT ETHYL have transformed it from a medication to a key component in the dietary supplements sector over time. How this potent omega 3 fatty acid was originally utilized to reduce levels but is now commonly included in different health supplements for overall well being enhancement. The effect of this shift in application is evident in the rising market demand for these supplements. This has led to heightened consumer knowledge and inclination, towards living options.

2

Pioneering in Cardiovascular Treatments:

ICOSAPENT ETHYLs significant shift in the industry focuses on advancing health marking a notable milestone in treatment innovation according- to experts who see its potential to transform heart attack and stroke prevention after successful clinical trials demonstrated its effectiveness It not only expands treatment choices, for cardiovascular health but also spurs more research and development in the field.

Global Events Shaping Future Growth

The chart below highlights how external events including emerging market developments, regulatory changes, and technological disruptions, have added another layer of complexity to the Nutraceuticals industry. These events have disrupted supply networks, changed consumption behavior, and reshaped growth patterns. Together with structural industry transitions, they demonstrate how changes within the Nutraceuticals industry cascade into the Icosapent Ethyl market, setting the stage for its future growth trajectory.

Market Dynamics and Supply Chain

Driver: Increasing Prevalence of Cardiovascular Diseases, and Favorable Government Regulations

The rise in diseases worldwide is also driving the need for ICOSAPENT ETHYL to lower triglycerides linked to heart problems in the bloodstream as well as to meet the needs of an aging population which is also likely to boost the market, for ICOSAPENT ETHYL in the coming years.
Countries around the world are also introducing rules and programs to encourage the adoption of APIs such as ICOSAPENT ETHYL in response to the growing demand for efficient cardiovascular therapies. These official actions are also stimulating market expansion. Creating a setting that supports additional exploration and innovation, in ICOSAPENT ETHYL.
There have also been advancements in the field of cardiovascular medicine development and delivery systems throughout the years that greatly impact the improvement of ICOSAPENT ETHYLs effectiveness and accessibility. Modern pharmaceutical technologies enable dosage delivery and enhanced absorption rates while promoting better patient adherence to treatment regimens – factors that are also expected to increase the demand, for this medication even more.

Restraint: Limited Awareness about ICOSAPENT ETHYL

Although ICOSAPENT ETHYL provides advantages for managing cardiovascular health and lowering triglyceride levels there is a lack of widespread knowledge about the product among the general public. This limited awareness hinders its market expansion since potential customers are often uninformed about its benefits and how to use it. The interest decreases because of the lack of attention and understanding of its therapeutic uses and application, in different health scenarios where it could play a crucial role.

Challenge: Regulatory Constraints

In the field of pharmaceuticals industry regulations can sometimes slow down market expansion efforts which is certainly the case, for the ICOSAPENT ETHYL market where getting approval involves dealing with strict processes and navigating through complicated patent laws and regulatory frameworks posing major obstacles to progress for companies requiring time and resources to get their products approved. A challenge also faced by ICOSAPENT ETHYL.

Supply Chain Landscape

Raw Material Procurement

Amneal Pharmaceuticals

West-Ward Pharmaceuticals

API Production

Matinas BioPharma

Amarin Pharma

Drug Formulation & Packaging
Catalent / Thermo Fisher Scientific
Distribution & End Users
AmerisourceBergen Corporation / Cardinal Health
Raw Material Procurement

Amneal Pharmaceuticals

West-Ward Pharmaceuticals

API Production

Matinas BioPharma

Amarin Pharma

Drug Formulation & Packaging

Catalent

Thermo Fisher Scientific

Distribution & End Users

AmerisourceBergen Corporation

Cardinal Health

Banner LogoBanner Logo

Leading Providers and Their Strategies

Application AreaIndustryLeading Providers / ConsumersProvider Strategies
Cardiovascular Health
Pharmaceutical
Amarin Corporation
Market penetration strategy with a focused emphasis on cardiovascular patient population
Hypertriglyceridemia
Pharmaceutical
GlaxoSmithKline
Aggressive research and development movements, aiming for novel treatment methods for hypertriglyceridemia
Nutritional Supplements
Health and Wellness
NutriGold Inc.
Growth strategies centered on product authenticity and sustainability, leveraging the health benefits of ICOSAPENT ETHYL
Dietary Management
Nutrition and Dietetics
GNC Holdings Inc.
Strategic partnerships and innovative product developments to drive customer engagement

Elevate your strategic vision with in-depth analysis of key applications, leading market players, and their strategies. The report analyzes industry leaders' views and statements on the Icosapent Ethyl market's present and future growth.

Our research is created following strict editorial standards. See our Editorial Policy

Applications of Icosapent Ethyl in Clinical Research Trials, Dietary Supplement Manufacturing and Cardiovascular Disease Management

Clinical Research Trials

ICOSAPENT ETHYL is an element in various clinical research studies focusing on the expanding realm of neurology where scientists utilize its neuroprotective qualities to delve into new treatment approaches for conditions, like Alzheimers and Parkinsons disease.

Dietary Supplement Manufacturing

Another way ICOSAPENT ETHYL is commonly used is in creating supplements because of its natural origins and importance in supporting heart health. Its often included in omega‐3 capsule supplements that can help people improve their diets and maintain their well being overall; major players in the dietary supplement industry such as NOW Foods and Nature Made emphasize the quality of their omega‐ enriched products, with ICOSAPENT ETHYL.

Cardiovascular Disease Management

ICOSAPENT ETHYL is commonly used in the management of heart conditions as a therapy for controlling diet to lower triglyceride levels in adult patients with severe hypertriglyceridemia This substance is made from omega 3 fatty acids and is known for its unique way of reducing triglyceride production Pfizer and GlaxoSmithKline are key players in this field who utilize the targeted approach of this compound to provide improved treatment choices, for cardiovascular issues that show encouraging outcomes.

Icosapent Ethyl vs. Substitutes:
Performance and Positioning Analysis

Compared to its alternatives, ICOSAPENT ETHYL offers superior cardiovascular benefits, positioning it uniquely in the market with robust growth potential. These Alternatives specially Krill Oil has experienced a rapid growth as detailed in our latest report.

Icosapent Ethyl
    Effective in reducing triglyceride levels, Offers protection against cardiovascular events
    Possible side effects including joint pain and sore throat, High cost may limit accessibility
    Effective in reducing triglyceride levels, fewer side effects
    Potential for drug interactions, Not as widely researched as ICOSAPENT ETHYL

Icosapent Ethyl vs. Substitutes:
Performance and Positioning Analysis

Icosapent Ethyl

  • Effective in reducing triglyceride levels, Offers protection against cardiovascular events
  • Possible side effects including joint pain and sore throat, High cost may limit accessibility

Omega 3 fatty acids / Krill Oil / Flaxseed Oil

  • Effective in reducing triglyceride levels, fewer side effects
  • Potential for drug interactions, Not as widely researched as ICOSAPENT ETHYL

Compared to its alternatives, ICOSAPENT ETHYL offers superior cardiovascular benefits, positioning it uniquely in the market with robust growth potential. These Alternatives specially Krill Oil has experienced a rapid growth as detailed in our latest report.

Loading...

Research Methodology

This market research methodology defines the Icosapent Ethyl market scope, gathers reliable data, and validates findings using integrated primary and secondary research. Our systematic framework ensures precise market sizing, growth trend analysis, and competitive benchmarking.


Secondary Research Approach


We begin secondary research by defining the targeted market at Country and Regional levels. As part of the Nutraceuticals ecosystem, we analyze Icosapent Ethyl across Pharmaceutical & Biotech Companies, Research Institutes, and Healthcare Facilities Applications. Our team gathers data systematically from country level ministerial sources, industry associations & federations, trade databases, company annual & quarterly reports and other credential sources, enabling us to map global and regional market size, pricing trends, regulatory standards, and technology advancements.


Key Sources Referenced:


We benchmark competitors such as Amarin Corporation plc, Chong Kun Dang Pharmaceuticals Corp., and Hikma Pharmaceuticals Plc by reviewing company financial statements, and regulatory filings. Our secondary insights identify key market drivers and constraints, forming the analytical foundation for primary research.


Primary Research Methods


We conduct structured interviews and surveys with industry stakeholders, including Raw Material Procurement, API Production, and Drug Formulation & Packaging. Our geographic coverage spans Americas (40%), Europe (30%), Asia-Pacific (25%) and Middle East & Africa (5%). Our online surveys generally achieve a response rate of above 65%, and telephone interviews yield 60%, resulting in above 92% confidence level with a ±7% margin of error.


Through targeted questionnaires and in-depth interviews, we capture purchase intent, adoption barriers, brand perception across Segment Type. We use interview guides to ensure consistency and anonymous survey options to mitigate response bias. These primary insights validate secondary findings and align market sizing with real-world conditions.


Market Engineering & Data Analysis Framework


Our data analysis framework integrates Top-Down, Bottom-Up, and Company Market Share approaches to estimate and project market size with precision.


Top-down & Bottom-Up Process


In Top-down approach, we disaggregate global Nutraceuticals revenues to estimate the Icosapent Ethyl segment, using historical growth patterns to set baseline trends. Simultaneously, in Bottom-up approach, we aggregate Country-Level Demand Data to derive regional and global forecasts, which provide granular consumption insights. By reconciling both approaches, we ensure statistical precision and cross-validation accuracy.


We evaluate the supply chain, spanning Raw Material Procurement (Amneal Pharmaceuticals, West-Ward Pharmaceuticals), API Production (Matinas BioPharma, Amarin Pharma), and Drug Formulation & Packaging. Our parallel substitute analysis examines Omega 3 fatty acids, Krill Oil, and Flaxseed Oil, highlighting diversification opportunities and competitive risks.


Company Market Share & Benchmarking


We benchmark leading companies such as Amarin Corporation plc, Chong Kun Dang Pharmaceuticals Corp., and Hikma Pharmaceuticals Plc, analyzing their capabilities in pricing, product features, technology adoption, and distribution reach. By assessing company-level revenues and product portfolios, we derive market share comparisons, clarifying competitive positioning and growth trajectories across the ecosystem.


Our integration of data triangulation, supply chain evaluation, and company benchmarking, supported by our proprietary Directional Superposition methodology enables us to deliver precise forecasts and actionable strategic insights into the Icosapent Ethyl market.


Quality Assurance and Compliance


We cross-reference secondary data with primary inputs and external expert reviews to confirm consistency. Further, we use stratified sampling, anonymous surveys, third-party interviews, and time-based sampling to reduce bias and strengthen our results.


Our methodology is developed in alignment with ISO 20252 standards and ICC/ESOMAR guidelines for research ethics. The study methodology follows globally recognized frameworks such as ISO 20252 and ICC codes of practice.

rm

Icosapent Ethyl Market Data: Size, Segmentation & Growth Forecast

Report AttributeDetails
Market Value in 2025USD 1.3 billion
Revenue Forecast in 2034USD 5.1 billion
Growth RateCAGR of 16.3% from 2025 to 2034
Base Year for Estimation2024
Industry Revenue 20241.1 billion
Growth OpportunityUSD 4.0 billion
Historical Data2019 - 2023
Growth Projection / Forecast Period2025 - 2034
Market Size UnitsMarket Revenue in USD billion and Industry Statistics
Market Size 20241.1 billion USD
Market Size 20271.8 billion USD
Market Size 20292.4 billion USD
Market Size 20302.8 billion USD
Market Size 20345.1 billion USD
Market Size 20355.9 billion USD
Report CoverageMarket revenue for past 5 years and forecast for future 10 years, Competitive Analysis & Company Market Share, Strategic Insights & trends
Segments CoveredDosage Form, Therapy Area, Manufacturing Process, End-User
Regional scopeNorth America, Europe, Asia Pacific, Latin America and Middle East & Africa
Country scopeU.S., Canada, Mexico, UK, Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Mexico, Argentina, Saudi Arabia, UAE and South Africa
Companies ProfiledAmarin Corporation plc, Chong Kun Dang Pharmaceuticals Corp., Hikma Pharmaceuticals Plc, Indian Immunologicals Ltd., InvaGen Pharmaceuticals Inc., Mayne Pharma Group Ltd., NorthStar Rx LLC, Sawai Pharmaceutical Co. Ltd., Sciegen Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd. and Zydus Cadila Healthcare Ltd.
CustomizationFree customization at segment, region or country scope and direct contact with report analyst team for 10 to 20 working hours for any additional niche requirement which is almost equivalent to 10% of report value

Explore Report Features and Data Packages

Industry Insight Report

$ 4200
Unlock Multi-User Access for just $999 more
i
No Payment Before Report Delivery
Flexible Payment Options
Additional Features
Customization Available
i
Excel Data Pack Included
Free Analyst Support
i
Industry Expert-Validated Insights
100% Confidentiality Guaranteed
Fast Delivery (24–72 hours)
i
Get Report Now

Strategic Growth Advisory

Unrivaled Custom Market Intelligence & Strategic Advisory for Business Growth and Competitive Excellence

  • Assess and prioritize high-value markets with precision
  • Craft tailored entry and expansion roadmaps
  • De-risk investments through rigorous market intelligence
  • Architect dynamic pricing frameworks aligned to value creation
  • Unlock sustainable margin enhancement opportunities
  • Benchmark performance against global industry leaders
  • Strategically realign portfolios to future growth drivers
  • Accelerate commercialization of breakthrough offerings
  • Harness market foresight and technology shifts to fuel innovation

Discover our Strategic Growth Advisory Services »

Table of Contents

Industry Insights Report - Table Of Contents

Chapter 1

Executive Summary

Major Markets & Their Performance - Statistical Snapshots

Chapter 2

Research Methodology

2.1Axioms & Postulates
2.2Market Introduction & Research MethodologyEstimation & Forecast Parameters / Major Databases & Sources
Chapter 3

Market Dynamics

3.1Market OverviewDrivers / Restraints / Opportunities / M4 Factors
3.2Market Trends
3.2.1Introduction & Narratives
3.2.2Market Trends - Impact Analysis(Short, Medium & Long Term Impacts)
3.3Supply Chain Analysis
3.4Porter's Five ForcesSuppliers & Buyers' Bargaining Power, Threat of Substitution & New Market Entrants, Competitive Rivalry
Chapter 4

Icosapent Ethyl Market Size, Opportunities & Strategic Insights, by Dosage Form

4.1Oral Drug
4.2Injectable Formulation
4.3Topical Administration
Chapter 5

Icosapent Ethyl Market Size, Opportunities & Strategic Insights, by Therapy Area

5.1Cardiovascular Diseases
5.2Hypertriglyceridemia
5.3Dietary Supplement
5.4Others
Chapter 6

Icosapent Ethyl Market Size, Opportunities & Strategic Insights, by Manufacturing Process

6.1Chemical Synthesis
6.2Biological Process
Chapter 7

Icosapent Ethyl Market Size, Opportunities & Strategic Insights, by End-User

7.1Pharmaceutical & Biotech Companies
7.2Research Institutes
7.3Healthcare Facilities
7.4Others
Chapter 8

Icosapent Ethyl Market, by Region

8.1North America Icosapent Ethyl Market Size, Opportunities, Key Trends & Strategic Insights
8.1.1U.S.
8.1.2Canada
8.2Europe Icosapent Ethyl Market Size, Opportunities, Key Trends & Strategic Insights
8.2.1Germany
8.2.2France
8.2.3UK
8.2.4Italy
8.2.5The Netherlands
8.2.6Rest of EU
8.3Asia Pacific Icosapent Ethyl Market Size, Opportunities, Key Trends & Strategic Insights
8.3.1China
8.3.2Japan
8.3.3South Korea
8.3.4India
8.3.5Australia
8.3.6Thailand
8.3.7Rest of APAC
8.4Middle East & Africa Icosapent Ethyl Market Size, Opportunities, Key Trends & Strategic Insights
8.4.1Saudi Arabia
8.4.2United Arab Emirates
8.4.3South Africa
8.4.4Rest of MEA
8.5Latin America Icosapent Ethyl Market Size, Opportunities, Key Trends & Strategic Insights
8.5.1Brazil
8.5.2Mexico
8.5.3Rest of LA
8.6CIS Icosapent Ethyl Market Size, Opportunities, Key Trends & Strategic Insights
8.6.1Russia
8.6.2Rest of CIS
Chapter 9

Competitive Landscape

9.1Competitive Dashboard & Market Share Analysis
9.2Company Profiles (Overview, Financials, Developments, SWOT)
9.2.1Amarin Corporation plc
9.2.2Chong Kun Dang Pharmaceuticals Corp.
9.2.3Hikma Pharmaceuticals Plc
9.2.4Indian Immunologicals Ltd.
9.2.5InvaGen Pharmaceuticals Inc.
9.2.6Mayne Pharma Group Ltd.
9.2.7NorthStar Rx LLC
9.2.8Sawai Pharmaceutical Co. Ltd.
9.2.9Sciegen Pharmaceuticals Inc.
9.2.10Teva Pharmaceutical Industries Ltd.
9.2.11Torrent Pharmaceuticals Ltd.
9.2.12Zydus Cadila Healthcare Ltd.